U.S. Markets closed

Changes in GlaxoSmithKline’s Valuation

Mike Benson

As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.